Video Lectures
State-of-the-industry video lectures by leading urology experts
Latest Videos

ORLANDO, FL USA (UroToday.com) -

Immune checkpoint inhibitors in CRPC

Dr. Charles Drake showed early results on immune checkpoint inhibitors in patients with metastatic prostate cancer. He started by showing a dramatic response in an RCC patient. He continued by showing exciting response rates to nivolumab in 34 patients with different types of tumors, but noted that none of the castration-resistant prostate cancer (CRPC) patients responded. Dr. Drake hypothesized that this may be because of intratumoral heterogeneity that Dr. Logothetis had previously discussed.

auaOn the heels of this study, ipilumumab was tested in a phase 1 trial of CRPC patients, and this trial actually showed that there was a response. Embedded into the trial was a combination of radiation, and while ipilumumab did not show an increase in response, the trial was small.

Disappointingly, a phase 3 study of ipilumumab in post-docetaxel CPRC patients did not show a difference in the primary endpoint, which was median overall survival (OS). On substratification, however, patients without visceral metastasis did have a response in median OS, and this might be a basis for further trials.

In trying to identify causes for treatment failure, his group showed a CD8:CD4 ratio of 1:2 in CRPC tissue, which is flip-flopped from what is typically found in blood or other tissues and tumors. He hypothesized that CD4 cells might actually be stimulating prostate cancer and that their depletion from tumors may increase therapeutic efficacy of immune checkpoint inhibitors. In order to normalize the CD8:CD4 ratio in prostate tumors (with the intent to increase immune modulator efficacy), he described a randomized trial testing GVAX, degarelix and cyclophosphamide (which depletes tissue CD4 cells), versus degarelix alone, which is currently accruing. He showed data from the first patient which suggested that typical markers like FoxP3 (a T-reg marker) and PD-1 may not be present as expected in prostate cancer-associated T cells. This may be a hurdle to overcome in order to make CRPC amenable to immune checkpoint inhibition.

AUA/NCI Specialized Programs of Research Excellence (SPORE) Joint Workshop

Presented by Charles G. Drake, MD, PhD at the American Urological Association (AUA) Annual Meeting - May 16 - 21, 2014 - Orlando, Florida USA

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD TX USA

Written by Phillip Abbosh, MD, PhD, medical writer for UroToday.com

 

Calendar
Upcoming urology industry events
February 24, 2018 / Charleston Marriott
Advances in Cancer Immunotherapy™ - Charleston, SC
February 24, 2018 /
2018 IUA Annual Meeting
February 26-27, 2018 / The Royal Marsden Hospital
MediSens – The European Medical Imaging Conference
February 27-March 3, 2018 /
SUFU 2018 Winter Meeting
March 1-3, 2018 / Omni Amelia Island Plantation Resort, Fernandina Beach, FL
75th Annual Meeting Mid-Atlantic Section of the American Urological Association
Journals
Print publications focusing on urological cancer treatments through original commentary & articles

Everyday Urology™ - Oncology Insights

From the Editor

Prostate Cancer and Prostatic Diseases

From the Editor

@UroToday